Newsletter
Treatment of agitation in Alzheimer disease, text messaging for CV risk modification, a newly approved PCSK9 inhibitor for dyslipidemia, and more.

JAMA Editor’s Summary

Treatment of agitation in Alzheimer disease, text messaging for CV risk modification, a newly approved PCSK9 inhibitor for dyslipidemia, and more.

Editor's Audio Summary by Howard Bauchner, MD, Editor in Chief of JAMA, the Journal of the American Medical Association, for the
September 22, 2015

Treatment of agitation in Alzheimer disease, text messaging for CV risk modification, a newly approved PCSK9 inhibitor for dyslipidemia, and more.

Editor’s Audio Summary by Howard Bauchner, MD, Editor in Chief of JAMA, the Journal of the American Medical Association, for the September 22/29, 2015 issue

Listen on your favorite player

New to Podcasts? It's easy to get started!

You may also like

The Latest Health Podcasts. Delivered to Your Inbox.

Join Our Newsletter

We gratefully acknowledge the many organizations that have generously supported our podcasts and platform.

Network Sponsors and Advertisers

Event and Media Partners

Buffer LinkedIn WhatsApp